The EU-CARDIOPROTECTION COST action (CA16225) is featured as a success story in Impact Assessment Study on Innovation in COST Actions, see the complete report as well as the article. The COST Association has commissioned Technopolis with carrying out an impact assessment to better understand impact pathways that lead to innovation.

‘We are proud to have been involved in the EU-CARDIOPROTECTION COST action. It was a great opportunity to work with cardioprotection researchers from across Europe and the world as well as to commercialize the unique multicenter small and large animal studies for myocardial infarction and heart failure as result of the know-how and network of the sites developed during the grant.’ said Prof. Péter Ferdinandy, MD, PhD, MBA, Founder & CEO of Pharmahungary Group.

Pharmahungary, the SME partner will utilize the know-how of preclinical multicenter trials according to the agreement with the consortium. For more informaiton on this unique service see or contact us directly.